Doxorubicin
Hydrochloride Injection, USP
| General Information: Doxorubicin
Hydrochloride Injection, USP is typically utilized to produce regression in disseminated neoplastic conditions
and as a component of adjuvant therapy in women with evidence of
axillary lymph node involvement. For indication, dosing and other information, please refer to the manufacture package insert. |
| |
| Manufacturer |
Product |
Size |
NDC |
PI |
MSDS |
|
TEVA |
Doxorubicin
|
200mg/100mL |
00703-5040-01 |
PI |
MSDS |
|
|
|
50mg/25mL |
00703-5046-01 |
PI |
MSDS |
|
|
|
10mg/5mL |
00703-5043-03 |
PI |
MSDS |
|
|
|
|
|
|
|
|
Pfizer |
Doxorubicin |
10mg/5mL |
00069-3030-20 |
PI |
MSDS |
|
|
|
20mg/10mL |
00069-3031-20 |
PI |
MSDS |
|
|
|
50mg/25mL |
00069-3032-20 |
PI |
MSDS |
|
|
|
150mg/75mL |
00069-3033-20 |
PI |
MSDS |
|
|
|
200mg/100mL |
00069-3034-20 |
PI |
MSDS |
|
| |
| Clinical
Data: For any questions
or for further information
related to Doxorubicin
Hydrochloride
Injection, USP clinical
pharmacology, additional
indications and usages,
contraindications, warnings,
precautions, adverse reactions,
dosage, administration and/or
storage of this product, please
contact
BDI Pharma or call 1-800-948-9834. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |